

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA354 Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA261 Rivaroxaban for the treatment and secondary prevention of venous thromboembolism, and TA287 Rivaroxaban for the treatment of acute symptomatic pulmonary embolism with or without symptomatic DVT and the prevention of recurrent VTE

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer-Ingelheim (dabigatran etexilate) • Bristol-Myers Squibb Pharmaceuticals (apixaban) • Daiichi Sankyo (edoxaban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Anticoagulation Europe • Arrhythmia Alliance • Atrial Fibrillation Association • Blood Pressure UK • British Lung Foundation • Cardiomyopathy UK • Cardiovascular Care Partnership • Muslim Council of Britain • Network of Sikh Foundations • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Surgeons of Great Britain and Ireland • British Association of Stroke Physicians • British Atherosclerosis Society • British Cardiovascular Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Allergan (warfarin) • Alliance Pharma (acenocoumarol) • Bayer (rivaroxaban) • Bristol Laboratories (warfarin) • Concordia International (phenindione, warfarin)

<ul style="list-style-type: none"> • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Hypertension Society • British Nuclear Cardiology Society • British Orthopaedic Association • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • Clinical Leaders of Thrombosis • Nurses Hypertension Association • Royal College of Anaesthetists • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Oxfordshire CCG • NHS Swindon CCG • Welsh Government 	<ul style="list-style-type: none"> • Crescent Pharma (warfarin) • GlaxoSmithKline (fondaparinux) • LEO Pharma (tinzaparin) • Mercury Pharmaceuticals (phenindione, warfarin) • Pfizer (dalteparin) • Sandoz (warfarin) • Sanofi (enoxaparin) • Taro Pharmaceuticals UK (warfarin) • Teva UK (warfarin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Department • Circulation Foundation • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Stroke Group • Cochrane Vascular • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Centre Cardiovascular Preventions and Outcomes • National Institute for Health Research • The Society for Research in Rehabilitation • Thrombosis Research Institute • Wellcome Trust <p><u>Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.